Follow
Tumor & Immunity
Tumors and the immune response interact in various ways. Tumors try to suppress the immune response in an effort to promote their growth and survival. The anti-tumor immune response, on the other hand, identifies tumor cells and kills them. Both tumors and the immune response elicit various mechanisms to combat the actions of the other.
OCT 07, 2021 | 7:30 AM
Advances in cancer research have improved our understanding of the complex interactions between tumors, their microenvironment and the host immune response. The evolving research field of im...
OCT 06, 2021 | 9:00 AM
Background: Localized prostate cancer is notable for tumor heterogeneity, and immune heterogeneity within tumor versus benign areas. B7-H3, a member of the B7 superfamily, is highly expresse...
SEP 22, 2021 | 11:59 PM
T cells exquisitely discriminate between antigenic and self-peptide ligands presented on major histocompatibility complexes (pMHCs) despite subtle differences in affinities. This aspect of a...
SEP 22, 2021 | 12:00 PM
While providing indispensable insight into immune processes, the live cell imaging of immune cells poses unique challenges due to their non-adherent nature. Suspension cells such as immune c...
SEP 08, 2021 | 9:00 AM
Date: September 8, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Implanted biomedical devices comprise a major component of modern medicine and are essential for many clinical applications ranging...
AUG 26, 2021 | 7:00 AM
Date: August 26, 2021 Time: 7:00am (PDT), 10:00am (EDT) Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with rising incidence and a remarkable resistance to current therapies. In t...
JUL 22, 2021 | 5:00 PM
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
JUL 22, 2021 | 12:00 PM
T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral...
JUN 17, 2021 | 7:00 AM
DATE: June 17, 2021 TIME: 07:00am PDT Colorectal cancer is a particularly challenging disease for immunotherapy given tumor heterogeneity. Multiplexed whole slide imaging allows deep context...
JUN 02, 2021 | 3:00 PM
PD-L1 is a key inhibitor of T cell activation that is often over-expressed in cancer to escape immune surveillance and promote tumor progression. Blocking antibodies against PD-L1 or its rec...